CLINICAL RESEARCH at Salem Hospital
Bringing tomorrow's therapies to our community today
Summary of Open Oncology Protocols
For more information contact Oncology Clinical Research at 503-561-2618.
Select Oncology Protocol Site:
Site: Bone Mets
Protocol: C70604
Title A Randomized Phase
III Study of
Standard Dosing
versus Longer
Dosing Interval of
Zoledronic Acid in
Metastatic Cancer
Treatment
Eligibility Histologic documentation of prostate or breast adenocarcinoma or multiple myeloma. At least one bone met by radiographic imaging. No prior IV bisphosphonate treatment. No prior radiopharmaceuticals. At least 4 weeks from completion of prior radiation ther
Protocol: SWOG S0702
Title A Prospective
Observational
Multicenter Cohort
Study to Assess the
Incidence of
Osteonecrosis of
the Jaw (ONJ) in
Cancer Patients
with Bone
Metastases Starting
Zoledronic Acid
Treatment
Treatment
Eligibility Bone mets from multiple myeloma, solid tumor, or other malignancy where bisphosphanate is indicated. Planned treatment with zoledronic acid. Less than or equal to 3 doses IV ibandronate, pamidronate, or zoledronic acid in past 3 years for osteopenia or o
Site: Brain
Protocol: RTOG R0825
Title Phase III
Double-Blind
Placebo-Controlled
Trial of
Conventional
Concurrent
Chemoradiation and
Adjuvant
Temozolomide Plus
Bevacizumab Versus
Conventional
Concurrent
Chemoradiation and
Adjuvant
Temozolomide in
Patients With Newly
Diagnosed
Glioblastoma
Treatment
Eligibility Must have newly diagnosed, histo confirmed GBM or gliosarcoma (WHO grade IV) confirmed by central pathology office. Must have supratentorial component. Must have preop and postop MRI. Labs to be WNL. No mets detected below the tentorium or beyond the cran
Site: Breast
Protocol: ECOG E5103
Title A Double-Blind Phase
III Trial of
Doxorubicin and
Cyclophosphamide
followed by
Paclitaxel with
Bevacizumab or
Placebo in Patients
with Lymph Node
Positive and High
Risk Lymph Node
Negative Breast
Cancer
Treatment
Eligibility Histologically confirmed adenocarcinoma of the breast at significant risk of distant recurrence based on at least one of the following: Involvement of 1 lymph node on routine histologic exam; ER negative >/= 1 cm; ER+ tumor >/+ 5 cms regardless of recurre
Protocol: NSABP B-39 /
Title A Randomized Phase
III Study of
Conventional Whole
Breast Irradiation
(WBI) vs Partial
Breast Irradiation
(PBI) for Women
with Stage 0, I, or
II Breast Cancer
Treatment
Eligibility Stage 0, 1, or 2 breast cancer. If stage 2, tumor size must be <3cm. Clear margins. No more than 3 histological positive axillary nodes. Women who are >50 with DCIS only, or over 50 with invasive, node neg and hormone positive are not eligible.
Protocol: OHSU 4318
Title A Phase II
Open-Label Study of
Sorafenib Plus
Fulvestrant as
Salvage Therapy For
Hormone Receptor
Positive Metastatic
Breast Cancer
Failing Prior
Aromatase Inhibitor
Treatment
Treatment
Eligibility Incurable locally advanced or metastatic breast cancer with measurable or evaluable disease. Subjects with bone only mets that can be imaged with bone scan and MRI or bone scan and plain x-ray are eligible. Must be hormone receptor positive defined as >=1
Protocol: PACCT1
Title Phase III Randomized
Study of Adjuvant
Combination
Chemotherapy and
Hormonal Therapy vs
Adjuvant Hormonal
Therapy Alone in
Women With
Previously Resected
Axillary
Node-Negative
Breast Cancer With
Various Levels of
Risk for Recurrence
(TAILORx Trial)
Treatment
Eligibility ER Positive and/or PR Positive. Axillary Node Negative. Candidate for adjuvant cytotoxic therapy in addition to hormonal therapy.
Protocol: S0715
Title Randomized
Placebo-Controlled
Trial of Acetyl
L-Carnitine for the
Prevention of Taxane
Induced Neuropathy,
Phase III
Treatment
Eligibility
Protocol: SWOG S0230
Title Phase III Trial of
LHRH Analog
Administration
during Chemotherapy
to Reduce Ovarian
Failure following
Chemotherapy in
Early Stage,
Hormone-Receptor
Negative Breast
Cancer
Treatment
Eligibility Operable stage I, II, or IIIA invasive breast cancer. Tumors must be ER & PR negative. Must be premenopausal. Must have modified radical mastectomy or local excision plus axillary lymph node dissection and/or sentinel node. Planned treatment must include
Protocol: SWOG S0622
Title Phase II Studies of
Two Different
Schedules of
Dasatinib
(NSC-732517) in
Bone-Metastasis
Predominant
Metastatic Breast
Cancer
Treatment
Eligibility Women or men with Stage IV breast cancer which is bone-predominant.
Site: CML
Protocol: CSTI571A24
Title A Worldwide,
Observational
Registry collecting
Longitudinal Data on
the Management of
Chronic Myelogenous
Leukemia (CML)
Patients (The WORLD
CML Registry) in
Routine Practice
Treatment
Eligibility Diagnosed with any phase ph+ or bcr-abl confirmed CML within 6 months of entry into the Registry. Provided informed consent.
Site: Colon
Protocol: ECOG E5202
Title Randomized Phase III
Study Comparing
FOLFOX Chemotherapy
vs. FOLFOX
Chemotherapy with
Bevacizumab in
Patients with Stage
II Colon Cancer at
High Risk for
Recurrence to
Determine
Prospectively the
Prognostic Value of
Molecular Markers
Treatment
Eligibility Enrollment suspended pending update to Consent
Histologically confirmed adenocarcinoma of the colon that is Stage II (T3,4 NO,MO). Distal extent of tumor must be >/= 12 cm from the anal verge as determined via endoscopy or surgery. Patients must have >/=
Protocol: OHSU 3753
Title Phase II Study of
Erlotinib (Tarceva)
Alternating with
Chemotherapy for
Second-line
Treatment of
Metastatic
Colorectal Cancer
with Molecular
Correlates for p53
Pathway
Treatment
Eligibility Age 18-80. Biopsy proven unresectable metastatic adeno of the colon or rectum. Documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer. Measurable disease of at least >1cm. First-line treat
Site: Esophageal
Protocol: RTOG R0436
Title A Phase III Trial
Evaluating the
Addition of
Cetuximab to
Paclitaxel,
Cisplatin, and
Radiation for
Patients with
Esophageal Cancer
Who are Treated
Without Surgery
Treatment
Eligibility Histologically proven diagnosis, via endoscopy, of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction within 6 weeks of registration. All disease must be encompassed in the radiotherapy field. Stage T1N1MO; T2-4,Any N, M
Site: Head and Neck
Protocol: ECOG E1305
Title A Phase III
Randomized Trial of
Cisplatin and
Docetaxel with or
without Bevacizumab
In Patients with
Recurrent or
Metastatic Head and
Neck Cancer
Treatment
Eligibility Must have histological or cytologically confirmed Squamous cell (SCCHN) from any primary site. Must not have nasopharyngeal carcinoma of histologic types WHO 2 or 3 squamous that originated in the skin. Patients must have SCCHN that is either recurrent, i
Site: Lung
Protocol: C30607
Title Randomized, Phase
III,
Placebo-Controlled
Trial of Sunitinib
as Maintenance
Therapy in
Non-Progressing
Patients Following
an Initial Four
Cycles of
Platinum-Based
Combination
Chemotherapy in
Advanced, Stage
IIIB/IV Non-Small
Cell Lung Cancer
Treatment
Eligibility Histologic or cytologic stage IIIB or IV NSCLC. No brain mets or spinal cord compression. Patients must have received 4 cycles of platinum-based doublet therapy with or without bevacizumab. No evidence of disease progression. No prior adjuvant chemo for s
Protocol: ECOG E1505
Title A Phase III
Randomized Trial of
Adjuvant
Chemotherapy With
or Without
Bevacizumab for
Completely Resected
Stage IB-IIIA
Non-Small Cell Lung
Cancer (NSCLC)
Treatment
Eligibility Complete resection of Stage 1B (>4cm)- IIIA non-small cell lung cancer. Wedge resection or segmentectomy will not be accepted. Lymph node sampling is expected. Refer to protocol for specifics. Patients must be no less than 6 weeks and no more than 12 week
Protocol: RTOG R0617
Title A Randomized Phase
III Comparison of
Standard Dose
(60Gy)Versus High
Dose (74Gy)
Conformal
Radiotherapy with
Concurrent and
Consolidation
Carboplatin/Paclitaxel
+/- Cetuximab (IND
103444) in Patients
with Stage IIIA/IIIB
Non-Small Cell Lung
Cancer
Treatment
Eligibility Histo or cyto NSCLC within 12 weeks of registration. Tumor cosidered unresectable or inoperable. Must be stage IIIA or IIIB with no distant mets. No supraclavicular or contralateral hilar disease. For additional eligibility criteria contact Clinical Resea
Protocol: S0819
Title A Randomized, Phase
III Study Comparing
Carboplatin/Paclitaxel
or
Carboplatin/Paclitaxel/Bevacizumab
with or without
Concurrent
Cetuximab in
Patients with
Advanced Non-Small
Cell Lung
Cancer(NSCLC)
Treatment
Eligibility Histo or Cyto proven newly diagnosed Stage IV Adeno, large cell, squamous, or unspecified NSCLC, or recurrent disease after prev surg/RT. Pt with controlled(min 2 months)brain mets after tx&no residual neurological dysfuntion off steroids are eligible. Me
Protocol: SWOG S0802
Title A Randomized Phase
II Trial of Weekly
Topotecan with and
without AVE0005
(Aflibercept;
NSC-724770) in
Patients with
Platinum Treated
Extensive Stage
Small Cell Lung
Cancer (E-SCLC)
Treatment
Eligibility Histo/Cyto confirmed extensive stage small cell lung ca with progression or recurrence after receiving exactly one standard first-line platinum-containing regime. Measurable/non-measureable disease. Known brain mets ok only if pt has been treated and sta
Protocol: SWOG S9925
Title Lung Cancer Specimen
Repository Protocol,
Ancillary
Treatment
Eligibility Must be registered to a treatment protocol: S0536; S0424
Site: Lymphoma
Protocol: SWOG 8947
Title Central Lymphoma
Serum Repository
Protocol
Treatment
Eligibility Must be registered to a treatment protocol.
Protocol: SWOG 9245
Title Central Lymphoma
Repository Tissue
Procurement
Protocol for
Relapse or
Recurrent Disease
Treatment
Eligibility Must be registered to a treatment protocol: 8410; 8503; 8508; 8516; 8736; 8809; 8907; 8954; 9125; 9240; 9320; 9349; 9432; 9501; 9703; S9704; 9800
Site: Melanoma
Protocol: SWOG E1697
Title Phase III Randomized
Study of Four Weeks
High Dose IFN-a2b
in Stage T2bNo,
T3a-bNo, T4a-bNo,
and T1-4,
N1a,2a(microscopic)
Melanoma
Treatment
Eligibility Melanoma of a cutaneous orgin. Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a,. Patients must complete all primary therapy (wide exicision with or without lymphadenectomy) and be randomized within 84 days of their wide excision. No prior chemotherapy, ra
Protocol: SWOG S0826
Title Phase II Study of
SCH 727965 in Stage
IV Melanoma
Treatment
Eligibility Must have biopsy proven stage IV cutaneous/mucosal malignant melanoma. Ocular not eligible. Measurable/non measurable disease. Must have neg Brain CT/MRI within 42 days of reg. HX Brain Mets not eligible. Zubrod 0-1,18 yrs old or older.May have received u
Site: Pancreas
Protocol: SWOG S0727
Title A Phase I and
Randomized Phase II
Trial of Gemcitabine
+ Erlotinib
(NSC-718781) +
IMC-A12
(NSC-742460)vs.
Gemcitabine +
Erlotinib as
First-Line
Treatment in
Patients with
Metastatic
Pancreatic Cancer
Treatment
Eligibility Histo or Cyto confirmed pancreatic adenoca:Stg IV unresectable. Macro residual disease not eligible. No sig acites. NO prior chemo, hormonal tx, imunotx, chemo/rt for advanced/locally advanced pan ca. No prior Gemcitibine for any reason. Prior surg ok if
Site: Prostate
Protocol: OHSU 2734
Title A Randomized Phase
II Study of
Intermittent
Chemotherapy or
Intermittent
Chemotherapy with
Maintenance GM-CSF
in Patients with
Previously
Untreated
Metastatic Hormone
Refractory Prostate
Cancer
Treatment
Eligibility Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Protocol: RTOG R0534
Title A Phase III Trial of
Short Term Androgen
Deprivation with
Pelvic Lymph Node
or Prostate Bed
Only Radiotherapy
(Spport) in
Prostate Cancer
Patients with a
Rising PSA after
Radical
Prostatectomy
Treatment
Eligibility Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (NO) or lymph node status pathologically unknown (undissected pelvic lymph nodes); Post radical prostate
Site: Renal
Protocol: ECOG E2805
Title Adjuvant Sorafenib
or Sunitinib for
Unfavorable Renal
Carcinoma
Treatment
Eligibility Patients with histological or cytological confirmed RCC T1B, T2, T3 and T4 with any N. Patients must have undergone full surgical resection - radical or partial nephrectomy by either open or laparoscopic technique, with clear margins. Positive regional LN
Site: Tissue Registry
Protocol: OHSU 3082
Title Oregon Colorectal
Cancer Registry
Treatment
Eligibility Must be diagnosed with colorectal, endometrial, bladder or other HNPCC cancers
Protocol: OHSU 4919
Title Personalized Cancer
Medicine Registry:
A Registry of
Patients with
Molecularly
Characterized
Malignancies
Treatment
Eligibility Histologically or cytologically confirmed diagnosis of cancer.
Services
